Matching trials
1,853 results
- Efficacy, Tolerability, and Safety Study of DFN-15: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Tolerability, and Safety Study of DFN-15: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03006276).
- Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EinsteinChoiceComplete statistical analysis of the EinsteinChoice phase 3 trial of reduced-dose rivaroxaban for long-term prevention of recurrent symptomatic venous thromboembolism, including trial design, endpoints, hazard ratios, confidence intervals, safety, and statistical interpretation.
- ELEVATEIndependent statistical analysis of Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures: primary endpoint results, effect estimate with confidence interval,…
- Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eltrombopag Phase III Study In Chinese Chronic ITP Patients: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Phase III Study In Chinese Chronic ITP Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01762761).
- Elucidation of Acid-Induced Pulmonary Inflammation: Complete Statistical AnalysisIndependent statistical analysis of Elucidation of Acid-Induced Pulmonary Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361972).
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMERALDIndependent statistical analysis of Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE: primary endpoint results, effect estimate with confidence interval,…
- EMERGEComplete statistical analysis of the randomized phase 3 EMERGE trial of aducanumab in early Alzheimer's disease, including CDR-SB, MMSE, ADAS-Cog 13, ADCS-ADL-MCI, MMRM methodology, confidence intervals, p-values, and trial limitations.
- EMMYIndependent statistical analysis of Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EMPACT-MIIndependent statistical analysis of EMPACT-MI, the randomized, placebo-controlled phase 3 trial of empagliflozin 10 mg after myocardial infarction: covariate-adjusted Cox hazard ratio for heart failure hospitalisation or death, negative binomial rate ratios…
- EMPACTAIndependent statistical analysis of the randomized phase 3 EMPACTA trial evaluating tocilizumab in hospitalized participants with COVID-19 pneumonia, including trial design, endpoints, statistical methodology, reported safety data, and educational interpretation.
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): Complete Statistical AnalysisIndependent statistical analysis of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- ENCHANTEDIndependent statistical analysis of the ENCHANTED phase 3 factorial trial of low-dose versus standard-dose rtPA and intensive versus standard blood-pressure management in acute ischemic stroke.
- ENCOREIndependent statistical analysis of A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE): primary endpoint results, effect estimate with confidence…
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENDEAVORIndependent statistical analysis of Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: Complete Statistical AnalysisIndependent statistical analysis of EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- endTBIndependent statistical analysis of the phase 3 endTB trial (NCT02754765), evaluating newly approved drugs for multidrug-resistant tuberculosis, including trial design, the week 73 efficacy endpoint, planned statistical analysis, and interpretation.
- endTB-QIndependent statistical analysis of the phase 3 endTB-Q trial evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance.
- ENDURANCE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection: primary endpoint results, effect estimate with confidence…
- ENESTPathIndependent statistical analysis of A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.: primary endpoint results, effect estimate…
- ENFORCEIndependent statistical analysis of A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ENHANCEIndependent statistical analysis of Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- ENIGMAIndependent statistical analysis of the ENIGMA phase 3 randomized trial of Bacillus Clausii with oral rehydration therapy for diarrhea in children with gastroenteritis, including trial design, endpoints, planned statistical methods, and interpretation.
- ENSURE-AFA detailed statistical analysis of the ENSURE-AF phase 3 trial comparing edoxaban with warfarin in patients undergoing cardioversion for nonvalvular atrial fibrillation, including endpoint definitions, odds-ratio interpretation, confidence intervals, analysis populations, and…
- Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B: Complete Statistical AnalysisIndependent statistical analysis of Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ENTRUST-AF-PCIIndependent statistical analysis of Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ENVISIONIndependent statistical analysis of A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ENVISIONIndependent statistical analysis of A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ENZAMETIndependent statistical analysis of ENZAMET, a randomized phase 3 trial evaluating enzalutamide with androgen deprivation therapy for metastatic prostate cancer. Includes trial design, endpoints, planned analysis, and statistical interpretation.
- ePHex-OLEIndependent statistical analysis of An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EPIC-PEDSA detailed statistical analysis of EPIC-PEDS, a phase 3 single-group study of nirmatrelvir/ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe…
- EPIC-SRIndependent statistical analysis of EPIC-SR (NCT05011513), the randomized, placebo-controlled phase 2/3 trial of nirmatrelvir plus ritonavir in standard-risk COVID-19, covering the log-rank primary analysis, logistic-regression odds ratios, negative binomial modelling and serious…
- EPOCHIndependent statistical analysis of An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- EQUATORIndependent statistical analysis of Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: Complete Statistical AnalysisIndependent statistical analysis of Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ERADICATE HpIndependent statistical analysis of ERADICATE Hp - Treating Helicobacter Pylori With RHB-105: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01980095).
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ESCAPEIndependent statistical analysis of the ESCAPE phase 3 trial evaluating high-titer COVID-19 convalescent plasma versus standard plasma in COVID-19. Includes trial design, endpoints, planned statistical methodology, and interpretation of the registry record.
- EscapeIndependent statistical analysis of Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ESCAPeIndependent statistical analysis of Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01283009).
- ESETTIndependent statistical analysis of Established Status Epilepticus Treatment Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01960075).
- Esmolol for Treatment of Perioperative Tachycardia: Complete Statistical AnalysisIndependent statistical analysis of Esmolol for Treatment of Perioperative Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01208402).
- ESOGIAIndependent statistical analysis of the ESOGIA phase 3 randomized trial evaluating classical versus optimized treatment allocation strategies for patients over 70 years of age with stage IV non-small-cell lung cancer.